Imagion Biosystems Limited (ASX:IBX)

Imagion Biosystems Income Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.07	2.67	4.97	3.07	2.86
Revenue Growth (YoY)	-97.26%	-46.38%	61.87%	7.54%	5.88%
Cost of Revenue	2.1	0.4	5.25	3.62	2.7
Gross Profit	-2.03	2.26	-0.28	-0.54	0.15
Selling, General & Admin	1.47	2.62	10.28	7.98	5.76
Operating Expenses	1.48	3.01	11.47	9.09	6.17
Operating Income	-3.51	-0.75	-11.75	-9.63	-6.01
Interest Expense	-0.85	-1.14	-0.92	-0.17	-0.01
Currency Exchange Gain (Loss)	-0	0	-0.01	-0	-0
Other Non Operating Income (Expenses)	0.05	-0.18	0.2	-	-
Pretax Income	-4.31	-2.07	-12.47	-9.81	-6.02
Net Income	-4.31	-2.07	-12.47	-9.81	-6.02
Net Income to Common	-4.31	-2.07	-12.47	-9.81	-6.02
Shares Outstanding (Basic)	277	45	30	28	26
Shares Outstanding (Diluted)	277	45	30	28	26
Shares Change (YoY)	517.31%	47.45%	8.75%	7.04%	40.22%
EPS (Basic)	-0.02	-0.05	-0.41	-0.35	-0.23
EPS (Diluted)	-0.02	-0.05	-0.41	-0.35	-0.24
Free Cash Flow	-4.04	-1.27	-8.51	-8.58	-5.29
Free Cash Flow Per Share	-0.01	-0.03	-0.28	-0.31	-0.20
Gross Margin	-	84.95%	-5.63%	-17.75%	5.31%
Operating Margin	-4808.73%	-28.05%	-236.32%	-313.63%	-210.64%
Profit Margin	-5900.86%	-77.55%	-250.95%	-319.36%	-210.98%
Free Cash Flow Margin	-5536.97%	-47.67%	-171.13%	-279.44%	-185.16%
EBITDA	-3.5	-0.7	-11.59	-9.49	-5.9
EBITDA Margin	-	-26.27%	-233.12%	-	-206.47%
D&A For EBITDA	0.01	0.05	0.16	0.14	0.12
EBIT	-3.51	-0.75	-11.75	-9.63	-6.01
EBIT Margin	-	-28.05%	-236.32%	-	-210.64%
Revenue as Reported	0.07	2.67	4.97	3.07	2.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.